vs

Side-by-side financial comparison of Sound Financial Bancorp, Inc. (SFBC) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $9.5M, roughly 1.4× Sound Financial Bancorp, Inc.). Sound Financial Bancorp, Inc. produced more free cash flow last quarter ($7.0M vs $-2.1M).

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

SFBC vs XLO — Head-to-Head

Bigger by revenue
XLO
XLO
1.4× larger
XLO
$13.7M
$9.5M
SFBC
More free cash flow
SFBC
SFBC
$9.1M more FCF
SFBC
$7.0M
$-2.1M
XLO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SFBC
SFBC
XLO
XLO
Revenue
$9.5M
$13.7M
Net Profit
$10.4M
Gross Margin
Operating Margin
27.1%
-86.5%
Net Margin
75.7%
Revenue YoY
1.5%
Net Profit YoY
179.1%
EPS (diluted)
$0.87
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SFBC
SFBC
XLO
XLO
Q4 25
$9.5M
$13.7M
Q3 25
$9.8M
$19.1M
Q2 25
$10.4M
$8.1M
Q1 25
$9.2M
$2.9M
Q4 24
$9.4M
Q3 24
$9.1M
Q2 24
$8.6M
Q1 24
$8.6M
Net Profit
SFBC
SFBC
XLO
XLO
Q4 25
$10.4M
Q3 25
$1.7M
$-16.3M
Q2 25
$2.1M
$-15.8M
Q1 25
$1.2M
$-13.3M
Q4 24
Q3 24
$1.2M
Q2 24
$795.0K
Q1 24
$770.0K
Operating Margin
SFBC
SFBC
XLO
XLO
Q4 25
27.1%
-86.5%
Q3 25
21.3%
-10.1%
Q2 25
24.5%
-177.7%
Q1 25
15.9%
-472.7%
Q4 24
24.6%
Q3 24
15.6%
Q2 24
11.4%
Q1 24
10.9%
Net Margin
SFBC
SFBC
XLO
XLO
Q4 25
75.7%
Q3 25
17.3%
-85.4%
Q2 25
19.8%
-196.0%
Q1 25
12.7%
-452.7%
Q4 24
Q3 24
12.7%
Q2 24
9.2%
Q1 24
9.0%
EPS (diluted)
SFBC
SFBC
XLO
XLO
Q4 25
$0.87
$-3.74
Q3 25
$0.66
$-0.11
Q2 25
$0.79
$-0.16
Q1 25
$0.45
$-0.18
Q4 24
$0.74
Q3 24
$0.45
Q2 24
$0.31
Q1 24
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SFBC
SFBC
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$138.5M
$137.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$109.4M
$35.3M
Total Assets
$1.1B
$154.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SFBC
SFBC
XLO
XLO
Q4 25
$138.5M
$137.5M
Q3 25
$101.2M
$103.8M
Q2 25
$102.5M
$121.6M
Q1 25
$131.5M
$89.1M
Q4 24
$43.6M
Q3 24
$148.9M
Q2 24
$135.1M
Q1 24
$138.0M
Stockholders' Equity
SFBC
SFBC
XLO
XLO
Q4 25
$109.4M
$35.3M
Q3 25
$107.5M
$-8.1M
Q2 25
$106.0M
$7.1M
Q1 25
$104.4M
$10.7M
Q4 24
$103.7M
Q3 24
$102.2M
Q2 24
$101.3M
Q1 24
$101.0M
Total Assets
SFBC
SFBC
XLO
XLO
Q4 25
$1.1B
$154.7M
Q3 25
$1.1B
$133.7M
Q2 25
$1.1B
$133.8M
Q1 25
$1.1B
$103.7M
Q4 24
$993.6M
Q3 24
$1.1B
Q2 24
$1.1B
Q1 24
$1.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SFBC
SFBC
XLO
XLO
Operating Cash FlowLast quarter
$7.2M
$-2.0M
Free Cash FlowOCF − Capex
$7.0M
$-2.1M
FCF MarginFCF / Revenue
73.4%
-15.3%
Capex IntensityCapex / Revenue
1.8%
0.7%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$12.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SFBC
SFBC
XLO
XLO
Q4 25
$7.2M
$-2.0M
Q3 25
$3.8M
$-17.5M
Q2 25
$-494.0K
$-14.5M
Q1 25
$1.9M
$29.0M
Q4 24
$2.9M
Q3 24
$3.3M
Q2 24
$-4.0M
Q1 24
$3.5M
Free Cash Flow
SFBC
SFBC
XLO
XLO
Q4 25
$7.0M
$-2.1M
Q3 25
$3.8M
Q2 25
$-518.0K
$-14.9M
Q1 25
$1.8M
$29.0M
Q4 24
$2.9M
Q3 24
$3.2M
Q2 24
$-5.6M
Q1 24
$1.9M
FCF Margin
SFBC
SFBC
XLO
XLO
Q4 25
73.4%
-15.3%
Q3 25
38.3%
Q2 25
-5.0%
-184.0%
Q1 25
19.8%
988.3%
Q4 24
30.4%
Q3 24
35.5%
Q2 24
-65.4%
Q1 24
22.2%
Capex Intensity
SFBC
SFBC
XLO
XLO
Q4 25
1.8%
0.7%
Q3 25
0.4%
0.0%
Q2 25
0.2%
5.0%
Q1 25
0.4%
0.8%
Q4 24
0.8%
Q3 24
0.5%
Q2 24
18.7%
Q1 24
19.0%
Cash Conversion
SFBC
SFBC
XLO
XLO
Q4 25
-0.19×
Q3 25
2.24×
Q2 25
-0.24×
Q1 25
1.59×
Q4 24
Q3 24
2.84×
Q2 24
-5.05×
Q1 24
4.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons